Care solution for treating skin hemangioma and preparation method thereof

Abstract

The invention relates to the technical field of care solutions, and discloses a care solution for treating skin hemangioma and a preparation method thereof, the care solution comprises the following components by mass: 10-26 parts of an active component, 1-5 parts of sodium hyaluronate, 5-15 parts of glycerin, 3-10 parts of propylene glycol, 0.5-3 parts of azone, 0.1-1 part of menthol, 0.5-2 parts of phenoxyethanol and 0.1-0.5 part of ethylhexylglycerin. The care solution capable of inhibiting blood vessel growth and promoting cell apoptosis is obtained by specially limiting active components, and substances with anti-inflammatory and repairing effects are also added, so that the efficacy of the care solution is improved.

Description

Technical Field

[0001] The present invention relates to the technical field of care solutions, in particular to a care solution for treating skin hemangiomas and a preparation method thereof. Background Art

[0002] Cutaneous hemangiomas are the most common benign tumors in infants and young children, with an incidence of approximately 4%-5%, and are more common in females than males. Traditional treatments, such as surgical excision, laser therapy, and cryotherapy, are associated with significant trauma, scarring, and a high recurrence rate. For example, surgical excision can lead to skin defects and scarring, particularly for patients with facial or large-area hemangiomas, resulting in poor postoperative aesthetics. Laser therapy, while partially destroying blood vessels, can cause complications such as pain and hyperpigmentation, and is limited in effectiveness for deep-seated hemangiomas. Cryotherapy can easily lead to localized tissue necrosis, requiring prolonged healing and potentially leaving scars.

[0003] Existing skincare products primarily focus on moisturizing and basic skin care, but are ineffective in treating skin hemangiomas. While some hormonal skincare products can provide short-term symptom relief, long-term use can lead to side effects such as skin atrophy and hyperpigmentation, and may even stimulate hemangioma growth.

[0004] Based on this, providing a safe, effective and side-effect-free skin hemangioma care solution has important clinical significance. Summary of the Invention

[0005] In view of this, the present invention proposes a care solution for treating skin hemangiomas and a preparation method thereof, aiming to solve at least one of the problems in the background technology.

[0006] The present invention provides a care solution for treating skin hemangiomas, comprising the following components in parts by weight:

[0007] 10-26 parts of active ingredients, 1-5 parts of sodium hyaluronate, 5-15 parts of glycerin, 3-10 parts of propylene glycol, 0.5-3 parts of azone, 0.1-1 part of menthol, 0.5-2 parts of phenoxyethanol and 0.1-0.5 parts of ethylhexylglycerin.

[0008] Preferably, the active ingredients include curcumin, dipotassium glycyrrhizate and asiaticoside.

[0009] Preferably, the mass ratio of curcumin, dipotassium glycyrrhizate and asiaticoside is 1:1:1.

[0010] The present invention also provides a method for preparing the care solution for treating skin hemangiomas described in the above technical solution, comprising the following steps:

[0011] Mixing curcumin, dipotassium glycyrrhizate, and asiaticoside with water and performing a first stirring to obtain an active ingredient solution;

[0012] Mixing sodium hyaluronate, glycerin, propylene glycol and water and performing a second stirring to obtain a moisturizer solution;

[0013] The active ingredient solution and the moisturizer solution are mixed, and then azone and menthol are added, and stirred to obtain a mixed solution;

[0014] The pH value of the mixed solution is adjusted to 6.0-6.5, and then phenoxyethanol and ethylhexylglycerin are added, and the mixture is stirred and mixed to obtain the care solution for treating skin hemangioma.

[0015] Preferably, the mass ratio of curcumin to water in the first stirring is 1-2:2-3, the temperature is 45-55° C., and the time is 1-2 hours.

[0016] Preferably, the mass ratio of sodium hyaluronate to water in the second stirring is 1:5-6, and the second stirring is performed at room temperature for 20-40 minutes.

[0017] Preferably, the stirring time of the mixed solution is 30 to 40 minutes.

[0018] Preferably, adjusting the pH value of the mixed solution is specifically: adding citric acid and sodium citrate to the mixed solution to adjust the pH of the mixed solution.

[0019] Preferably, the preparation method further comprises: filtering the care solution for treating skin hemangiomas before packaging it, and then filling it into a sterile container.

[0020] Preferably, the filter membrane used for the filtration is a microporous filter membrane of 0.2 to 0.3 μm.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] By specifically limiting the active ingredients, the present invention obtains a care solution that can inhibit blood vessel growth and promote cell apoptosis. The present invention also adds substances with anti-inflammatory and repair effects to enhance the efficacy of the care solution. Specifically:

[0023] (1) Inhibit angiogenesis: Curcumin can inhibit the expression of vascular endothelial growth factor and its receptors, thereby blocking the angiogenesis signaling pathway and reducing the formation of new blood vessels. Dipotassium glycyrrhizate can inhibit the activity of matrix metalloproteinases, prevent the degradation of vascular basement membranes, and further inhibit angiogenesis.

[0024] (2) Promote cell apoptosis: Centella asiatica can induce apoptosis of hemangioma cells by activating the caspase cascade reaction, prompting hemangioma cells to enter the apoptosis program. Curcumin also has a similar effect and can promote cell apoptosis by regulating the expression of Bcl-family proteins.

[0025] (3) Anti-inflammatory and repair: Dipotassium glycyrrhizate has a strong anti-inflammatory effect, which can inhibit the release of inflammatory mediators such as histamine and prostaglandins, and reduce the inflammatory response around hemangiomas. Centella asiatica can promote skin repair and regeneration, accelerate wound healing, and reduce scar formation.

[0026] (4) Enhance drug penetration: Azone and menthol act as penetration enhancers, which can change the structure of the skin's stratum corneum, increase the transdermal absorption rate of drugs, and enable the active ingredients to reach the lesion site more effectively. DETAILED DESCRIPTION

[0027] Various exemplary embodiments of the present invention are now described in detail. This detailed description should not be considered as a limitation of the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention. It should be understood that the terms used in the present invention are only for describing specific embodiments and are not intended to limit the present invention.

[0028] In addition, for numerical ranges in the present invention, it is understood that each intervening value between the upper and lower limits of the range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated value or intervening value in the stated range is also included in the present invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.

[0029] Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of any conflict with any incorporated document, the contents of this specification shall prevail.

[0030] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from the description of the invention. The description and examples are intended to be exemplary only.

[0031] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0032] The present invention provides a care solution for treating skin hemangiomas, comprising the following components in parts by weight:

[0033] 10-26 parts of active ingredients, 1-5 parts of sodium hyaluronate, 5-15 parts of glycerin, 3-10 parts of propylene glycol, 0.5-3 parts of azone, 0.1-1 part of menthol, 0.5-2 parts of phenoxyethanol and 0.1-0.5 parts of ethylhexylglycerin.

[0034] The components of the present invention are preferably composed of 10-15 parts of active ingredient, 1-3 parts of sodium hyaluronate, 5-10 parts of glycerin, 3-7 parts of propylene glycol, 0.5-2 parts of azone, 0.1-0.5 parts of menthol, 0.5-1 parts of phenoxyethanol and 0.1-0.3 parts of ethylhexylglycerin.

[0035] In the present invention, the active ingredients include curcumin, dipotassium glycyrrhizate and asiaticoside.

[0036] In the present invention, the mass ratio of curcumin, dipotassium glycyrrhizate and asiaticoside is 1:1:1.

[0037] The present invention also provides a method for preparing the care solution for treating skin hemangiomas described in the above technical solution, comprising the following steps:

[0038] Mixing curcumin, dipotassium glycyrrhizate, and asiaticoside with water and performing a first stirring to obtain an active ingredient solution;

[0039] Mixing sodium hyaluronate, glycerin, propylene glycol and water and performing a second stirring to obtain a moisturizer solution;

[0040] The active ingredient solution and the moisturizer solution are mixed, and then azone and menthol are added, and stirred to obtain a mixed solution;

[0041] The pH value of the mixed solution is adjusted to 6.0-6.5, and then phenoxyethanol and ethylhexylglycerin are added, and the mixture is stirred and mixed to obtain the care solution for treating skin hemangioma.

[0042] Mixing curcumin, dipotassium glycyrrhizate, and asiaticoside with water and performing a first stirring to obtain an active ingredient solution;

[0043] In the present invention, the mass ratio of curcumin to water in the first stirring is preferably 1-2:2-3, the temperature is preferably 45-55° C., more preferably 45-50° C., and the time is preferably 1-2 hours.

[0044] The present invention first dissolves curcumin, dipotassium glycyrrhizate, and asiaticoside in water to obtain an active ingredient solution. Curcumin can inhibit the expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR), thereby blocking the angiogenesis signaling pathway and reducing the formation of new blood vessels. Dipotassium glycyrrhizate can inhibit the activity of matrix metalloproteinases (MMPs), preventing the degradation of vascular basement membranes and further inhibiting angiogenesis. Furthermore, asiaticoside can induce apoptosis of hemangioma cells by activating the caspase cascade reaction, prompting cancer cells to enter the apoptosis program. Curcumin also has a similar effect and can promote cell apoptosis by regulating the expression of Bcl-2 family proteins.

[0045] Mixing sodium hyaluronate, glycerin, propylene glycol and water and performing a second stirring to obtain a moisturizer solution;

[0046] In the present invention, the mass ratio of sodium hyaluronate to water in the second stirring is preferably 1:5 to 6, more preferably 1:5; the second stirring is performed at room temperature, and the time is preferably 20 to 40 minutes.

[0047] In the present invention, sodium hyaluronate, glycerin and propylene glycol are used as moisturizing ingredients. Specifically, sodium hyaluronate, as a natural glycosaminoglycan, has a strong water absorption capacity and can form a hydration film on the skin surface to lock in moisture; at the same time, it promotes the repair of the stratum corneum and enhances the skin barrier function; glycerin is a small molecule moisturizer, which enters the stratum corneum through penetration, combines with water molecules to form hydrogen bonds, and maintains the skin's hydration; at the same time, it enhances the solubility of other ingredients, promotes the uniform dispersion of active ingredients, and synergizes with sodium hyaluronate to make the skin moisturizing effect last for 6-8 hours, avoiding the impact of dry skin on drug absorption; propylene glycol, as a glycol moisturizer, has both moisturizing and solubilizing functions, which can reduce the hydrophobicity of active ingredients such as curcumin and improve its solubility in aqueous solution; at the same time, it increases the flexibility of the skin's stratum corneum and reduces dryness and cracking.

[0048] The active ingredient solution and the moisturizer solution are mixed, and then azone and menthol are added, and stirred to obtain a mixed solution;

[0049] In the present invention, the stirring time of the mixed solution is preferably 30 to 40 minutes.

[0050] The azone described in the present invention, as a highly effective transdermal penetration enhancer, can disrupt the lipid bilayer structure of the skin's stratum corneum, increase the intercellular spaces between corneocytes, and promote the penetration of active ingredients (such as curcumin and asiaticoside) through the epidermis to reach the hemangioma lesions in the dermis. Menthol, a natural terpenoid compound, stimulates the skin's cold receptors to produce a cooling sensation, alleviating the burning discomfort at the hemangioma site. It also dilates local capillaries, increasing skin blood flow and indirectly promoting drug absorption.

[0051] The pH value of the mixed solution is adjusted to 6.0-6.5, and then phenoxyethanol and ethylhexylglycerin are added, and the mixture is stirred and mixed to obtain the care solution for treating skin hemangioma.

[0052] The present invention adopts citric acid and sodium citrate as pH regulators to adjust the pH of the mixed solution so that the pH value of the care solution is close to the physiological pH value of the skin, thereby avoiding skin irritation caused by excessive acidity or alkalinity. Phenoxyethanol and ethylhexylglycerin are then added and mixed. The phenoxyethanol of the present invention serves as a preservative and inhibits the growth and reproduction of gram-positive bacteria, gram-negative bacteria and fungi by destroying the integrity of bacterial cell membranes, thereby preventing the care solution from deteriorating during storage. The ethylhexylglycerin serves as an auxiliary preservative and reduces the surface tension of bacterial cell membranes, thereby enhancing the antibacterial effect of phenoxyethanol. The care solution also has a certain moisturizing effect and alleviates the slight dryness that may be caused by phenoxyethanol.

[0053] In the present invention, adjusting the pH value of the mixed solution specifically comprises: adding citric acid and sodium citrate to the mixed solution to adjust the pH value of the mixed solution.

[0054] In the present invention, the preparation method further comprises: filtering the care solution for treating skin hemangiomas before packaging the care solution, and then filling the solution into a sterile container.

[0055] In the present invention, the filter membrane used for the filtration is preferably a microporous filter membrane with a diameter of 0.2 to 0.3 μm.

[0056] After obtaining the care solution, the present invention uses a microporous membrane filter before packaging. The 0.2-0.3 μm microporous membrane can effectively intercept bacteria, fungi, and spores, ensuring that the care solution meets sterility standards. For external use preparations that directly contact the wound surface, microbial contamination may lead to infection risks, especially in infants and young children with skin hemangiomas, who have weak immunity. Sterile filtration is a key guarantee of safety. In addition, microporous membrane filtration can intercept insoluble particles introduced during the production process, preventing them from affecting the feel of the care solution.

[0057] Example 1

[0058] (1) Mix 4 parts of curcumin, 4 parts of dipotassium glycyrrhizate, 4 parts of asiaticoside and 8 parts of water, stir at 45°C for 1 hour, and mix thoroughly to obtain an active ingredient solution;

[0059] (2) Mix 1 part sodium hyaluronate, 5 parts glycerin, 3 parts propylene glycol, and 5 parts water, stir at room temperature, and stir for 20 minutes to obtain a moisturizing solution;

[0060] (3) The active ingredient solution and the moisturizer solution were mixed, and then 0.5 parts of azone and 0.1 parts of menthol were added, and the mixture was stirred for 30 minutes to obtain a mixed solution after mixing evenly;

[0061] (4) adding citric acid and sodium citrate to the mixed solution to adjust the pH of the mixed solution so that the pH of the mixed solution is between 6.0 and 6.5, then adding 0.5 parts of phenoxyethanol and 0.1 parts of ethylhexylglycerin, and stirring evenly to obtain the care solution;

[0062] (5) The obtained care solution is filtered using a microporous filter membrane with a diameter of 0.22 μm. After filtration, it is packaged into a sterile container.

[0063] Example 2

[0064] (1) Mix 5 parts of curcumin, 5 parts of dipotassium glycyrrhizate, 5 parts of asiaticoside and 10 parts of water, stir at 50°C for 1 hour, and mix thoroughly to obtain an active ingredient solution;

[0065] (2) mixing 3 parts of sodium hyaluronate, 10 parts of glycerin, 7 parts of propylene glycol, and 15 parts of water, stirring at room temperature for 30 minutes to obtain a moisturizing solution;

[0066] (3) The active ingredient solution and the moisturizer solution were mixed, and then 2 parts of azone and 0.5 parts of menthol were added, and the mixture was stirred for 30 minutes to obtain a mixed solution after mixing evenly;

[0067] (4) adding citric acid and sodium citrate to the mixed solution to adjust the pH of the mixed solution so that the pH of the mixed solution is between 6.0 and 6.5, then adding 1 part of phenoxyethanol and 0.3 parts of ethylhexylglycerin, and stirring evenly to obtain the care solution;

[0068] (5) The obtained care solution is filtered using a microporous filter membrane with a diameter of 0.22 μm. After filtration, it is packaged into a sterile container.

[0069] Example 3

[0070] (1) 6 parts of curcumin, 6 parts of dipotassium glycyrrhizate, 6 parts of asiaticoside and 12 parts of water were mixed and stirred at 55° C. for 2 hours to obtain an active ingredient solution after mixing uniformly;

[0071] (2) 5 parts of sodium hyaluronate, 15 parts of glycerin, 10 parts of propylene glycol and 25 parts of water were mixed and stirred at room temperature for 40 minutes to obtain a moisturizing solution;

[0072] (3) The active ingredient solution and the moisturizer solution were mixed, and then 2 parts of azone and 0.5 parts of menthol were added, and the mixture was stirred for 30 minutes to obtain a mixed solution after mixing evenly;

[0073] (4) adding citric acid and sodium citrate to the mixed solution to adjust the pH of the mixed solution so that the pH of the mixed solution is between 6.0 and 6.5, then adding 2 parts of phenoxyethanol and 0.5 parts of ethylhexylglycerin, and stirring evenly to obtain the care solution;

[0074] (5) The obtained care solution is filtered using a microporous filter membrane with a diameter of 0.22 μm. After filtration, it is packaged into a sterile container.

[0075] Test Case

[0076] The care solution obtained in Example 1 was used as the experimental group, and the commercially available common moisturizing solution was used as the control group (the main components of the commercially available common moisturizing solution were hyaluronic acid and aloe extract).

[0077] (1) Establishing cell models and animal models

[0078] Cell model: Human hemangioma endothelial cells (HHEC) were purchased from the cell bank of the Chinese Academy of Sciences and cultured in DMEM medium containing 10% fetal bovine serum.

[0079] Animal model: SPF nude mice (4 weeks old, weighing 18-22 g) were subcutaneously inoculated with HHEC cells (1×10 6 A total of 30 rats were randomly divided into 3 groups (10 rats in each group).

[0080] (2) Testing

[0081] Perform cell proliferation inhibition experiment on the cell model

[0082] HHEC cells were seeded in 96-well plates (5 × 103 cells / well). After 24 h of culture, the experimental group, control group 1, and control group 2 nursing solution (final concentration 50 μg / mL) were added, and the blank group was added with an equal amount of culture medium. After 48 h of culture, MTT solution (5 mg / mL) was added and incubated for 4 h. The absorbance at 490 nm (OD value) was measured with a microplate reader, and the cell proliferation inhibition rate was calculated: Inhibition rate (%) = (1-OD value of experimental group / OD value of blank group) × 100%

[0083] Animal model efficacy evaluation

[0084] Nude mice in the experimental group received a daily application of the experimental care solution (0.1 mL / time) to their dorsal tumors for four consecutive weeks. Control group 1 received a commercially available care solution, while control group 2 received a blank care solution. Tumor volume was measured weekly (volume = length × width × 2 × 0.52), and the volume reduction rate was calculated as follows: Volume reduction rate (%) = (initial volume - volume after four weeks) / initial volume × 100%. After four weeks, the mice were sacrificed, and tumor tissue was obtained for HE staining to determine vascular density (number of vessels per field of view).

[0085] (3) Results

[0086] The test results of the cell model are shown in Table 1

[0087] Table 1 Cell model test results

[0088] Group OD value (490nm) Proliferation inhibition rate Experimental group 0.39±0.05 68.8±4.0 control group 1.18±0.07 5.6±5.6

[0089] The test results of the animal model are shown in Table 2

[0090] Table 2 Animal model test results

[0091]

[0092] Based on Tables 1 and 2, it can be seen that the inhibition rate of HHEC in the experimental group was significantly higher than that in the control group (P < 0.01). The tumor reduction rate in the experimental group was the highest and the blood vessel density was the lowest (P < 0.01), indicating that the care solution obtained by the present invention can exert its therapeutic effect by inhibiting angiogenesis.

[0093] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit it. Although the present invention has been described in detail with reference to the above embodiments, ordinary technicians in the field should understand that the specific implementation methods of the present invention can still be modified or replaced by equivalents. Any modification or equivalent replacement that does not depart from the spirit and scope of the present invention should be covered by the scope of protection of the claims of the present invention.

Claims

1. A care solution for treating skin hemangioma, characterized in that: The composition includes the following parts by weight: 10-26 parts of active ingredients, 1-5 parts of sodium hyaluronate, 5-15 parts of glycerin, 3-10 parts of propylene glycol, 0.5-3 parts of azone, 0.1-1 part of menthol, 0.5-2 parts of phenoxyethanol and 0.1-0.5 parts of ethylhexylglycerin.

2. The care solution for treating skin hemangioma according to claim 1, characterized in that: The active ingredients include curcumin, dipotassium glycyrrhizate and asiaticoside.

3. The care solution for treating skin hemangioma according to claim 2, characterized in that: The mass ratio of the curcumin, dipotassium glycyrrhizate and asiaticoside is 1:1:

1.

4. A method for preparing a care solution for treating skin hemangioma according to any one of claims 1 to 3, comprising the following steps: Mixing curcumin, dipotassium glycyrrhizate, and asiaticoside with water and performing a first stirring to obtain an active ingredient solution; Mixing sodium hyaluronate, glycerin, propylene glycol and water and performing a second stirring to obtain a moisturizer solution; The active ingredient solution and the moisturizer solution are mixed, and then azone and menthol are added, and stirred to obtain a mixed solution; The pH value of the mixed solution is adjusted to 6.0-6.5, and then phenoxyethanol and ethylhexylglycerin are added, and the mixture is stirred and mixed to obtain the care solution for treating skin hemangioma.

5. The preparation method according to claim 4, characterized in that In the first stirring, the mass ratio of curcumin to water is 1-2:2-3, the temperature is 45-55° C., and the time is 1-2 hours.

6. The preparation method according to claim 4, characterized in that The mass ratio of sodium hyaluronate to water in the second stirring is 1:5-6, and the second stirring is performed at room temperature for 20-40 minutes.

7. The preparation method according to claim 4, characterized in that The stirring time of the mixed solution is 30 to 40 minutes.

8. The preparation method according to claim 4, characterized in that The pH value of the mixed solution is adjusted specifically by adding citric acid and sodium citrate to the mixed solution to adjust the pH value of the mixed solution.

9. The preparation method according to claim 4, characterized in that The preparation method further comprises: filtering the care solution for treating skin hemangiomas before packaging, and then filling it into a sterile container.

10. The preparation method according to claim 8, characterized in that The filter membrane used in the filtration is a 0.2-0.3 μm microporous filter membrane.

Images